Real-world data confirms CRISPR gene therapy has cured sickle cell disease in over 100 patients, with zero vaso-occlusive crises post-treatment.
Real-world evidence published in the journal Blood confirms that CRISPR-based gene therapy has effectively cured sickle cell disease in over 100 patients treated since the therapy received FDA approval in December 2023. None of the treated patients have experienced vaso-occlusive crises, the painful and potentially life-threatening episodes that characterize the disease, in the follow-up period.
The therapy, marketed as exa-cel (Casgevy), works by editing the BCL11A gene in the patient's own blood stem cells. This reactivates fetal hemoglobin production, which compensates for the defective adult hemoglobin that causes red blood cells to sickle. Patients undergo bone marrow conditioning before receiving the modified stem cells, which then engraft and produce healthy blood cells.
The real-world data, collected from 23 treatment centers across the United States and Europe, closely mirrors the results from clinical trials. Average fetal hemoglobin levels rose from less than 1% before treatment to over 40% at one year post-treatment. Total hemoglobin levels normalized in 95% of patients, eliminating the chronic anemia that contributes to organ damage.
Patients report dramatic improvements in quality of life. Many who previously required monthly blood transfusions and frequent hospital admissions for pain management are now living without these interventions. Several patients have returned to full-time employment or education for the first time in years.
The primary barrier to broader access remains cost. The therapy is priced at $2.2 million per patient, reflecting the complex manufacturing process and the decades of research behind it. However, health economic analyses suggest the one-time treatment is cost-effective over a patient's lifetime compared to the estimated $1.6 million in lifetime management costs for sickle cell disease.
Several payers, including Medicaid programs in states with high sickle cell prevalence, have negotiated outcomes-based contracts that tie payment to documented clinical benefit. International efforts are underway to bring the therapy to sub-Saharan Africa, where the majority of the world's estimated 300,000 annual sickle cell births occur.
Researchers are now investigating whether similar gene editing approaches can be applied to beta-thalassemia, hemophilia, and other monogenic blood disorders.